Stocktoria
Equillium, Inc. EQ
Nasdaq · XNAS · stock · Pharmaceutical Preparations · website · IPO 2018-10-12
Equillium, Inc. financials (annual, from 10-K)
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | — | $41.1M | $36.1M | $15.8M | — |
| R&D expense | — | — | $37.0M | $37.5M | $26.4M |
| Operating income | -$23.6M | -$8.3M | -$14.5M | -$62.1M | -$37.8M |
| Income tax | $0 | $361,000 | $580,000 | $0 | $0 |
| Net income | -$22.4M | -$8.1M | -$13.3M | -$62.4M | -$39.1M |
| EPS (diluted) | $-0.39 | $-0.23 | $-0.38 | $-1.85 | $-1.36 |
| Operating cash flow | -$22.7M | -$19.0M | -$21.8M | -$8.7M | -$32.1M |
| Free cash flow | -$22.8M | -$19.1M | -$21.8M | -$9.0M | -$32.1M |
| Cash & equivalents | $30.3M | $18.1M | $23.2M | $59.1M | $50.4M |
| Total assets | $31.9M | $25.6M | $50.5M | $78.4M | $85.4M |
| Total liabilities | $3.3M | $6.5M | $28.0M | $46.5M | $18.9M |
| Shareholders' equity | $28.6M | $19.1M | $22.6M | $31.9M | $66.5M |
Source: SEC EDGAR filings · CIK 0001746466 · as of 2025-12-31. Facts from filings plus Stocktoria's own computed scores — not investment advice.